1. 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results. (31st December 2020) Authors: Chounta, Vasiliki; Bernal, Enrique; Lombaard, Johan; Katner, Harold P; Walmsley, Sharon; Dorey, David; Spreen, William; Griffith, Sandy; Margolis, David Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 626. The Efficacy and Safety of Maintenance with Doravirine Plus Two NRTIs after Initial Suppression in Adults with HIV-1 in the DRIVE-FORWARD Clinical Trial: Results from the Study Extension through 192 Weeks. (4th December 2021) Authors: Cahn, Pedro; Molina, Jean-michel; Lombaard, Johan; Squires, Kathleen; Kumar, Sushma; Wan, Hong; Teal, Valerie; Asante-Appiah, Ernest; Sklar, Peter; Martin, Elizabeth A; Lahoulou, Rima Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Issue 1 (January 2017) Authors: Boyd, Mark A; Amin, Janaki; Mallon, Patrick W G; Kumarasamy, Nagalingeswaran; Lombaard, Johan; Wood, Robin; Chetchotisakd, Ploenchan; Phanuphak, Praphan; Mohapi, Lerato; Azwa, Iskandar; Belloso, Waldo H; Molina, Jean-Michel; Hoy, Jennifer; Moore, Cecilia L; Emery, Sean; Cooper, David A Journal: Lancet Issue: Volume 4:Issue 1(2017) Page Start: e13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Issue 5 (May 2018) Authors: Molina, Jean-Michel; Squires, Kathleen; Sax, Paul E; Cahn, Pedro; Lombaard, Johan; DeJesus, Edwin; Lai, Ming-Tain; Xu, Xia; Rodgers, Anthony; Lupinacci, Lisa; Kumar, Sushma; Sklar, Peter; Nguyen, Bach-Yen; Hanna, George J; Hwang, Carey Journal: Lancet Issue: Volume 5:Issue 5(2018) Page Start: e211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Issue 1 (January 2020) Authors: Molina, Jean-Michel; Squires, Kathleen; Sax, Paul E; Cahn, Pedro; Lombaard, Johan; DeJesus, Edwin; Lai, Ming-Tain; Rodgers, Anthony; Lupinacci, Lisa; Kumar, Sushma; Sklar, Peter; Hanna, George J; Hwang, Carey; Martin, Elizabeth Anne Journal: Lancet Issue: Volume 7:Issue 1(2020) Page Start: e16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Issue 10330 (19th March 2022) Authors: Bekker, Linda-Gail; Garrett, Nigel; Goga, Ameena; Fairall, Lara; Reddy, Tarylee; Yende-Zuma, Nonhlanhla; Kassanjee, Reshma; Collie, Shirley; Sanne, Ian; Boulle, Andrew; Seocharan, Ishen; Engelbrecht, Imke; Davies, Mary-Ann; Champion, Jared; Chen, Tommy; Bennett, Sarah; Mametja, Selaelo; Semenya, ... Journal: Lancet Issue: Volume 399:Issue 10330(2022) Page Start: 1141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies. Issue 6 (November 2021) Authors: Molina, Jean Michel; Ene, Luminita; Cahn, Pedro; Fätkenheuer, Gerd; Van Wijngaerden, Eric; Lombaard, Johan; Zakharova, Natalia; Van Eygen, Veerle; Vanveggel, Simon; Van Solingen-Ristea, Rodica Journal: Antiviral therapy Issue: Volume 26:Issue 6/8(2021) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. (23rd May 2019) Authors: Orkin, Chloe; Molina, Jean-Michel; Lombaard, Johan; DeJesus, Edwin; Rodgers, Anthony; Kumar, Sushma; Martin, Elizabeth; Hanna, George; Hwang, Carey Journal: Clinical infectious diseases Issue: Volume 70:Number 7(2020) Page Start: 1344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics. Issue 11 (November 2016) Authors: Lombaard, Johan; Bunupuradah, Torsak; Flynn, Patricia M.; Ramapuram, John; Ssali, Francis; Crauwels, Herta; Hoogstoel, Annemie; Van Eygen, Veerle; Stevens, Marita Journal: Pediatric infectious disease journal Issue: Volume 35:Issue 11(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗